Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer

Front Immunol. 2023 Aug 9:14:1231315. doi: 10.3389/fimmu.2023.1231315. eCollection 2023.

Abstract

Tertiary lymphoid structures (TLSs) are clusters of lymphoid cells with an organization that resembles that of secondary lymphoid organs. Both structures share common developmental characteristics, although TLSs usually appear in chronically inflamed non-lymphoid tissues, such as tumors. TLSs contain diverse types of immune cells, with varying degrees of spatial organization that represent different stages of maturation. These structures support both humoral and cellular immune responses, thus the correlation between the existence of TLS and clinical outcomes in cancer patients has been extensively studied. The finding that TLSs are associated with better prognosis in some types of cancer has led to the design of therapeutic strategies based on promoting the formation of these structures. Agents such as chemokines, cytokines, antibodies and cancer vaccines have been used in combination with traditional antitumor treatments to enhance TLS generation, with good results. The induction of TLS formation therefore represents a novel and promising avenue for the treatment of a number of tumor types.

Keywords: B cells; TLS modulation; adaptive anti-tumor response; immunotherapy; tertiary lymphoid structures.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies
  • B-Lymphocytes
  • Cancer Vaccines*
  • Humans
  • Neoplasms* / therapy
  • Tertiary Lymphoid Structures*

Substances

  • Antibodies
  • Cancer Vaccines

Grants and funding

This work was supported by Fondo de Investigaciones Sanitarias from Instituto de Salud Carlos III co-funded by the “Fondo Europeo de Desarrollo Regional FEDER” grants PI22/01542 and CIBER Cardiovascular to AA, and by the CRIS Clinical Talent Programme 2022 from ‘Fundación CRIS contra el Cancer’, and grants from ISCIII (PI21/01111) and Mutua Madrileña (AP176822021) to NR-L.